Showing 1 - 3 results of 3 for search 'Umesh Muchhal' Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Author
  • Umesh Muchhal
Showing 1 - 3 results of 3 for search 'Umesh Muchhal', query time: 0.08s Refine Results
  1. 1
    564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents
    564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agen...
    by Ke Liu, Christine Bonzon, Seung Chu, Rumana Rashid, Umesh Muchhal, John Desjarlais, Matthew Bernett, Nicole Rodriguez, Nargess Hassanzadeh-Kiabi, Connie Ardila
    Published 2020-11-01
    Article
  2. 2
    697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
    697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
    by Gregory Moore, Michael Hedvat, Christine Bonzon, Rumana Rashid, Umesh Muchhal, John Desjarlais, Irene Leung, Veronica Zeng, Juan Diaz, Kendra Avery, Norm Bartlow, Charles Bakhit, Matthew Dragovich, Liz Bogart
    Published 2020-11-01
    Article
  3. 3
    718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
    718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cance...
    by Cong Li, Gregory Moore, Umesh Muchhal, John Desjarlais, Matthew Bernett, Madeline Fort, Lingming Liang, Tao Osgood, Rodolfo Yabut, Sarav Kaliyaperumal, John Harrold, Jude Canon, Anna Rogojina, Raushan Kurmasheva, Peter Houghton, Olivier Nolan-Stevaux
    Published 2020-11-01
    Article
Search Tools: Get RSS Feed — Email this Search

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...